Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces 2016 Second Quarter Dividend

[PR Newswire] – THOUSAND OAKS, Calif., March 2, 2016 /PRNewswire/ — Amgen (AMGN) today announced that its Board of Directors declared a $1.00 per share dividend for the second quarter of 2016. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. Read more on this. Amgen Inc. (AMGN) , currently valued at $110.93B, began trading this morning at $148.00. Today’s price range has been between $146.21 and $148.63 per share with its 52-week range being $130.09 to $181.81. Amgen (AMGN) shares are currently priced at 13.15x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -0.27x earnings multiple for the same period. And for dividend hunters, the company pays shareholders $4.00 per share annually in dividends, yielding 2.71%. In a review of the consensus earnings estimate this quarter, 20 sell-side analysts are looking at $2.59 per share, which would be $0.11 better than the year-ago quarter and a $0.04 sequential increase. In looking at the bigger picture, the full-year EPS estimate of $10.82 would be a $0.44 better when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $5.29 Billion. If realized, that would be a 5.17% increase over the year-ago quarter. In terms of ratings, Citigroup Initiated AMGN at Neutral (Feb 25, 2016). Previously, Credit Suisse Initiated AMGN at to Outperform. The average price target for AMGN shares by the analysts covering the stock is $181.18, which is 22.42% above where the stock opened this morning. See more in (NASDAQ:AMGN) Similar Articles: Stock Update: Amgen Inc (NASDAQ:AMGN) – Unilife and Amgen Enter Strategic Collaboration for Injectable Drug Delivery Systems Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces 2015 Fourth Quarter Dividend